



## **Prior Authorization Request Form for Antipsychotics**

## FAX this completed form to (877) 386-4695

<u>OR</u> Mai	l requests to: Envolve Pharmacy	Solutions PA Depa	rtment	5 River Park	x Place East, Suite 210   Fresno, CA 93720		
I. PROVIDER INFORMATION			II. MEMBER INFORMATION				
Prescri	ber Name:		Member Name:				
Prescriber Specialty:			Identification #:				
Office (	Contact Name:		Group #:				
Group	Name:		Date of Birth:				
Fax #:			Medicati	ion Allergies:			
Phone	#:			-			
III. DI	RUG INFORMATION (One drug	g request per forn	n)				
		Dosage Interval (sig			Qty. per Day:		
	· · ·			mentation	demonstrating evidence for each		
item i	must be submitted with prior o	authorization requ	uest)				
Specify	y diagnosis & diagnosis code releva	ant to this request:	]	Dx/Dx Code:			
	er has taken the requested non-pro 0 days?	eferred antipsychotic	c in the	☐ Yes ☐ No	Submit documentation.		
have a	ests for all non-preferred medical history of trial and failure of or copreferred Antipsychotics? Refer to ist for a list of preferred and non-preferred and	ntraindication or into https://papdl.com/p	olerance <u>referred</u> -	□ Yes	Submit documentation of previous trials/failures, contraindications, and/or intolerances or current use.		
	peutic Duplication: currently prescribed a therapeutic sted):	duplicate (i.e. anothe	er Antipsy	chotics or do	ose different from the agent being		
	Member is being transitioned from edications	om one Antipsychotic	c to anoth	er with the ir	ntent of discontinuing one of the		
	Member has a medical reason fo literature or national treatment		the reque	ested medica	tions that is supported by peer-reviewed		
Ouant	ity Limit:						
	If requesting for daily quantity ex <u>Services/Pages/Quantity-Limits-ainformation:</u>	ceeding daily limit (F and-Daily-Dose-Limi	Refer to <u>h</u> tts.aspx), p	ttps://www. blease provid	dhs.pa.gov/providers/Pharmacy- le supporting		
	IT MEDICAL RECORD INFORMATI	ON FOR EACH APPLI	CABLE IT	ЕМ.			
REQUEST FOR INVEGA:  Member has a history of therapeutic failure, contraindication or intolerance of the preferred  Antipsychotics:							
	Member has active liver disease v		is at risk	for active liv	rer disease		
REQUE	ST FOR A LOW-DOSE ORAL ANTI	PSYCHOTIC FOR MI	EMBER 1	8 YEARS OF	AGE OF OLDER:		
	Low dose prescribed is part of a p	_	nerapeutio	c dose			
•	ST FOR A MEMBER LESS THAN 1						
	-1						
	Prescribed by or in consultation with a child development pediatrician, general psychiatrist (only if member is older than 14 years old), child & adolescent psychiatrist or pediatric neurologist:						

Member has had a comprehensive evaluation as evident by chart notes (chart notes need to be provided)   Member has tried non-drug therapy (evidence-based behavioral, cognitive, and family based therapies) as evident by chart notes:   Member has the following baseline and/or follow-up monitoring. Check all that apply and submit documentation for each.   BMI (or weight and height):   Billood pressure:   Fasting glucose level:   Fasting glucose level:   Fasting glucose level:   Gasting glucose level:   Fasting splucose level:   Fasting splucose level:   BMI or weight monitored quarterly:   Fasting glucose level:   Fasting glucose level:   Fasting glucose level:   Fasting glucose level:   Pasting glucose level:   Pasting glucose level:   Pasting splucose le		to: Aut	Member has severe behavioral problems related to psychotic or neuro-developmental disorder such as, but not limited to: Autism spectrum disorder, Intellectual disability, Conduct disorder, Bipolar disease, Tic disorder (including Tourette's syndrome), Transient encephalopathy, Schizophrenia:								
Member has tried non-drug therapy (evidence-based behavioral, cognitive, and family based therapies) as evident by chart notes:   Member has the following baseline and/or follow-up monitoring. Check all that apply and submit documentation for each.   BMI (or weight and height):		Mank and a community and a community and a single property of the second and the									
chart notes:    Member has the following baseline and/or follow-up monitoring. Check all that apply and submit documentation for each.   BMI (or weight and height):											
Member has the following baseline and/or follow-up monitoring. Check all that apply and submit documentation for each.   BMI (or weight and height):											
BMI (or weight and height): Blood pressure: Fasting glucose level: Fasting lipid panel: Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS): AIMS): RENEWAL REQUESTS FOR A MEMBER LESS THAN 18 YEARS OF AGE:		Memb									
Blood pressure:     Fasting glucose level:											
Fasting glucose level:											
Fasting lipid panel:			•								
Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS):    Member has the following baseline and/or follow-up monitoring. Check all that apply and submit documentation for each.    Improvement in target symptoms evident by:   BMI or weight monitored quarterly:   Bill or weight monitored quarterly:   Fasting glucose level:   Fasting lipid panel:   Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) after the first 3 months then annually:   Plan for taper/discontinuation of the Antipsychotic or rational for continued use:   RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:   Documentation of tolerability and experienced a positive clinical response to requested medication evident by:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:    Appropriate clinical information to support the request on   Provider Signature:   Date:											
(AIMS):   RENEWAL REQUESTS FOR A MEMBER LESS THAN 18 YEARS OF AGE:			Fasting lipid panel:								
RENEWAL REQUESTS FOR A MEMBER LESS THAN 18 YEARS OF AGE:    Member has the following baseline and/or follow-up monitoring. Check all that apply and submit documentation for each.    Improvement in target symptoms evident by:   BMI or weight monitored quarterly:   BMI or weight monitored quarterly:   Fasting glucose level:   Fasting lipid panel:   Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) after the first 3 months then annually:   Plan for taper/discontinuation of the Antipsychotic or rational for continued use:   RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:   Documentation of tolerability and experienced a positive clinical response to requested medication evident by:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :  Appropriate clinical information to support the request on   Provider Signature:   Date:			Presence of extrapyramidal symptoms (EPS) us	sing the Abnormal Involuntary Movement	Scale						
Member has the following baseline and/or follow-up monitoring. Check all that apply and submit documentation for each.			(AIMS):		<del></del>						
each.    Improvement in target symptoms evident by:   BMI or weight monitored quarterly:   Blood pressure:   Fasting glucose level:   Fasting lipid panel:   Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) after the first 3 months then annually:   Plan for taper/discontinuation of the Antipsychotic or rational for continued use:   RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:   Documentation of tolerability and experienced a positive clinical response to requested medication evident by:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:    Appropriate clinical information to support the request on   Provider Signature:   Date:	RENEW										
Improvement in target symptoms evident by:   BMI or weight monitored quarterly:   Blood pressure:   Fasting glucose level:   Fasting glucose level:   Fasting lipid panel:   Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) after the first 3 months then annually:   Plan for taper/discontinuation of the Antipsychotic or rational for continued use:   RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:   Documentation of tolerability and experienced a positive clinical response to requested medication evident by:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:    Appropriate clinical information to support the request on   Provider Signature:   Date:											
BMI or weight monitored quarterly:   Blood pressure:   Fasting glucose level:   Fasting lipid panel:   Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) after the first 3 months then annually:   Plan for taper/discontinuation of the Antipsychotic or rational for continued use:   RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:   Documentation of tolerability and experienced a positive clinical response to requested medication evident by:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :   Date:   D			Improvement in target symptoms evident by								
Blood pressure:   Fasting glucose level:   Fasting glucose level:   Fasting glucose level:   Fasting glucose level:   Fasting lipid panel:   Presence of extrappyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) after the first 3 months then annually:   Plan for taper/discontinuation of the Antipsychotic or rational for continued use:   RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:   Documentation of tolerability and experienced a positive clinical response to requested medication evident by:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :   Date:   Date:   Date:   Date:											
Fasting glucose level:   Fasting lipid panel:   Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) after the first 3 months then annually:   Plan for taper/discontinuation of the Antipsychotic or rational for continued use:   RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:   Documentation of tolerability and experienced a positive clinical response to requested medication evident by:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:    Appropriate clinical information to support the request on   Provider Signature:   Date:   Date:											
Fasting lipid panel:   Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) after the first 3 months then annually:   Plan for taper/discontinuation of the Antipsychotic or rational for continued use:   RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:   Documentation of tolerability and experienced a positive clinical response to requested medication evident by:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :   Date:   D											
Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) after the first 3 months then annually:  Plan for taper/discontinuation of the Antipsychotic or rational for continued use:  RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:  Documentation of tolerability and experienced a positive clinical response to requested medication evident by:  IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:  Appropriate clinical information to support the request on Provider Signature:  Date:			Fasting glucose level:								
first 3 months then annually:    Plan for taper/discontinuation of the Antipsychotic or rational for continued use:   RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:   Documentation of tolerability and experienced a positive clinical response to requested medication evident by:   IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:    Appropriate clinical information to support the request on   Provider Signature:   Date:		8 F F F									
Plan for taper/discontinuation of the Antipsychotic or rational for continued use:		Ц									
RENEWAL REQUESTS FOR A MEMBER 18 YEARS OF AGE OR OLDER:  Documentation of tolerability and experienced a positive clinical response to requested medication evident by:  IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:  Appropriate clinical information to support the request on Provider Signature: Date:			Dien Geneteren (die een binne als een een een een een een een een een ee		<del></del>						
Documentation of tolerability and experienced a positive clinical response to requested medication evident by:    V. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:    Appropriate clinical information to support the request on   Provider Signature:   Date:	RENEW	_	OHESTS FOR A MEMBER 18 VEARS OF ACE OR	OI DER.							
IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:  Appropriate clinical information to support the request on Provider Signature: Date:			<del>-</del>		ion evident						
IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:  Appropriate clinical information to support the request on Provider Signature: Date:	_			• •							
Appropriate clinical information to support the request on Provider Signature: Date:		~ J									
Appropriate clinical information to support the request on Provider Signature: Date:	IV AF	DITIC	NIAL DATIONALE FOR DEGLIECT / DEDTL	NENT CLINICAL INCODMATION.							
	IV. AL	אווועע	DNAL KATIONALE FOR REQUEST / PERTI	NENT CLINICAL INFORMATION:							
	Annro										
	טוטעה	priate c	linical information to support the request on	Provider Signature:	Date:						

Envolve Pharmacy Solutions will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)